Literature DB >> 3545463

Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity.

M Markman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3545463     DOI: 10.1016/0305-7372(86)90007-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  11 in total

1.  Percutaneous placement of peritoneal port-catheter in oncologic patients.

Authors:  Franco Orsi; Paolo Della Vigna; Silvia Penco; Guido Bonomo; Elena Lovati; Massimo Bellomi
Journal:  Eur Radiol       Date:  2004-06-18       Impact factor: 5.315

2.  Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.

Authors:  M Markman; W Jones; J L Lewis; S Rubin; T Hakes; B Reichman; R Barakat; J Curtin; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.

Authors:  Koichiro Haruki; Hiroaki Shiba; Yuki Fujiwara; Kenei Furukawa; Ryota Iwase; Tadashi Uwagawa; Takeyuki Misawa; Toya Ohashi; Katsuhiko Yanaga
Journal:  Dig Dis Sci       Date:  2012-07-18       Impact factor: 3.199

Review 4.  Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.

Authors:  Robert L Coleman; Anil K Sood
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

5.  Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.

Authors:  L T Vlasveld; B G Taal; B B Kroon; M P Gallee; S Rodenhuis
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  Intraperitoneal chemotherapy for ovarian cancer with peritoneal metastases, systematic review of the literature and focused personal experience.

Authors:  Federico Coccolini; Paola Fugazzola; Giulia Montori; Luca Ansaloni; Massimo Chiarugi
Journal:  J Gastrointest Oncol       Date:  2021-04

7.  Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.

Authors:  M Markman; B Reichman; T Hakes; R Barakat; J Curtin; S Rubin; W Jones; J L Lewis; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients.

Authors:  Michiya Kobayashi; Junichi Sakamoto; Tsutomu Namikawa; Ken Okamoto; Takehiro Okabayashi; Kengo Ichikawa; Keijiro Araki
Journal:  World J Gastroenterol       Date:  2006-03-07       Impact factor: 5.742

Review 9.  Intraperitoneal therapy in the management of ovarian carcinoma.

Authors:  M Markman; T Hakes; B Reichman; W Hoskins; S Rubin; W Jones; L Almadones; J L Lewis
Journal:  Yale J Biol Med       Date:  1989 Jul-Aug

10.  Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.

Authors:  G Pratesi; M Tortoreto; C Corti; R Giardini; F Zunino
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.